These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 10903326

  • 1. Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice.
    Ishigaki Y, Oikawa S, Suzuki T, Usui S, Magoori K, Kim DH, Suzuki H, Sasaki J, Sasano H, Okazaki M, Toyota T, Saito T, Yamamoto TT.
    J Biol Chem; 2000 Oct 06; 275(40):31269-73. PubMed ID: 10903326
    [Abstract] [Full Text] [Related]

  • 2. Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy.
    Saito T, Ishigaki Y, Oikawa S, Yamamoto TT.
    Trends Cardiovasc Med; 2002 Feb 06; 12(2):67-70. PubMed ID: 11852253
    [Abstract] [Full Text] [Related]

  • 3. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy.
    Hoffmann MM, Scharnagl H, Panagiotou E, Banghard WT, Wieland H, März W.
    J Am Soc Nephrol; 2001 Mar 06; 12(3):524-530. PubMed ID: 11181800
    [Abstract] [Full Text] [Related]

  • 4. Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice.
    Ishimura A, Watanabe M, Nakashima H, Ito K, Miyake K, Mochizuki S, Ishigaki Y, Saito T.
    Clin Exp Nephrol; 2009 Oct 06; 13(5):430-437. PubMed ID: 19459027
    [Abstract] [Full Text] [Related]

  • 5. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases.
    Saito T, Matsunaga A, Oikawa S.
    Am J Kidney Dis; 2006 Feb 06; 47(2):199-211. PubMed ID: 16431249
    [Abstract] [Full Text] [Related]

  • 6. Lipoprotein glomerulopathy induced by ApoE Kyoto mutation in ApoE-deficient mice.
    Wu H, Yang J, Liu YQ, Lei S, Yang M, Yang Z, Yang Y, Hu Z.
    J Transl Med; 2021 Mar 04; 19(1):97. PubMed ID: 33663537
    [Abstract] [Full Text] [Related]

  • 7. A founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy.
    Toyota K, Hashimoto T, Ogino D, Matsunaga A, Ito M, Masakane I, Degawa N, Sato H, Shirai S, Umetsu K, Tamiya G, Saito T, Hayasaka K.
    J Hum Genet; 2013 May 04; 58(5):254-8. PubMed ID: 23407349
    [Abstract] [Full Text] [Related]

  • 8. Plasma level and genetic variation of apolipoprotein E in patients with lipoprotein glomerulopathy.
    Zhang B, Liu ZH, Zeng CH, Zheng JM, Chen HP, Zhou H, Li LS.
    Chin Med J (Engl); 2005 Apr 05; 118(7):555-60. PubMed ID: 15820086
    [Abstract] [Full Text] [Related]

  • 9. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.
    Matsunaga A, Sasaki J, Komatsu T, Kanatsu K, Tsuji E, Moriyama K, Koga T, Arakawa K, Oikawa S, Saito T, Kita T, Doi T.
    Kidney Int; 1999 Aug 05; 56(2):421-7. PubMed ID: 10432380
    [Abstract] [Full Text] [Related]

  • 10. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor.
    van Dijk KW, van Vlijmen BJ, van der Zee A, van't Hof B, van der Boom H, Kobayashi K, Chan L, Havekes LM, Hofker MH.
    Arterioscler Thromb Vasc Biol; 1998 Jan 05; 18(1):7-12. PubMed ID: 9445249
    [Abstract] [Full Text] [Related]

  • 11. Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features.
    Saito T, Oikawa S, Sato H, Sato T, Ito S, Sasaki J.
    Kidney Int Suppl; 1999 Jul 05; 71():S37-41. PubMed ID: 10412734
    [Abstract] [Full Text] [Related]

  • 12. Apolipoprotein E-related glomerular disorders.
    Saito T, Matsunaga A, Fukunaga M, Nagahama K, Hara S, Muso E.
    Kidney Int; 2020 Feb 05; 97(2):279-288. PubMed ID: 31874799
    [Abstract] [Full Text] [Related]

  • 13. Clinicopathological and genetic characteristics in Chinese patients with lipoprotein glomerulopathy.
    Zhang B, Liu ZH, Zeng CH, Zheng JM, Chen HP, Li LS.
    J Nephrol; 2008 Feb 05; 21(1):110-7. PubMed ID: 18264944
    [Abstract] [Full Text] [Related]

  • 14. Lipoprotein glomerulopathy associated with the Osaka/Kurashiki APOE variant: two cases identified in Latin America.
    da Silveira-Neto JN, de Oliveira Ahn GJ, de Menezes Neves PDM, Baptista VAF, de Almeida Araújo S, Wanderley DC, Watanabe A, Watanabe EH, Murai NM, Bertollo EMG, Vieira-Neto OM, Dantas M, de Antônio SR, Costa RS, Baptista MASF, Moysés-Neto M, Onuchic LF.
    Diagn Pathol; 2021 Jul 26; 16(1):65. PubMed ID: 34311745
    [Abstract] [Full Text] [Related]

  • 15. Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy.
    Luo B, Huang F, Liu Q, Li X, Chen W, Zhou SF, Yu X.
    Am J Nephrol; 2008 Jul 26; 28(2):347-53. PubMed ID: 18046082
    [Abstract] [Full Text] [Related]

  • 16. Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia.
    Matsunaga A, Saito T.
    Clin Exp Nephrol; 2014 Apr 26; 18(2):220-4. PubMed ID: 24570178
    [Abstract] [Full Text] [Related]

  • 17. The Novel Apolipoprotein E Mutation ApoE Chengdu (c.518T＞C, p.L173P) in a Chinese Patient with Lipoprotein Glomerulopathy.
    Wu H, Yang Y, Hu Z.
    J Atheroscler Thromb; 2018 Aug 01; 25(8):733-740. PubMed ID: 29398675
    [Abstract] [Full Text] [Related]

  • 18. Clinical and genetic analysis of lipoprotein glomerulopathy patients caused by APOE mutations.
    Yang M, Weng Q, Pan X, Hussain HMJ, Yu S, Xu J, Yu X, Liu Y, Jin Y, Zhang C, Li X, Ren H, Chen N, Xie J.
    Mol Genet Genomic Med; 2020 Aug 01; 8(8):e1281. PubMed ID: 32441489
    [Abstract] [Full Text] [Related]

  • 19. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
    Kypreos KE, Li X, van Dijk KW, Havekes LM, Zannis VI.
    Biochemistry; 2003 Aug 26; 42(33):9841-53. PubMed ID: 12924933
    [Abstract] [Full Text] [Related]

  • 20. Lipoprotein glomerulopathy with markedly increased arterial stiffness successfully treated with a combination of fenofibrate and losartan: a case report.
    Kato J, Okonogi H, Kanzaki G, Katsumata H, Nakada Y, Sagasaki M, Komine K, Ito K, Saito T, Matsunaga A, Tokutou K, Honda K, Tsuboi N, Yokoo T.
    BMC Nephrol; 2024 May 20; 25(1):171. PubMed ID: 38769490
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.